No Data
Jointown Pharmaceutical Group (600998.SH) plans to carry out the filing and fundraising of Pre-REITs funds for pharmaceutical logistics warehousing.
Jointown Pharmaceutical Group (600998.SH) announced that, in order to further optimize the asset structure and enhance the efficiency of capital operation, the company...
Express News | Hubei Province Traditional Chinese Medicine Materials Association Established
Jointown Pharmaceutical Group (600998.SH): Intends to invest 0.245 billion yuan to establish the Jiuying Entrepreneurship Investment Fund.
Gelonghui, November 8th: Jointown Pharmaceutical Group (600998.SH) announced that, guaranteeing the necessary funds for daily operation, Jointown Pharmaceutical Group plans to jointly invest with Chuchang private equity fund to establish Wuhan Jiuying Entrepreneurship Investment Fund Partnership Enterprise (Limited Partnership) (tentatively named, subject to industrial and commercial approval, hereinafter referred to as "Jiuying Entrepreneurship Investment Fund"), with a planned total fundraising scale of 0.5 billion yuan. Among them, Jointown Pharmaceutical Group as a limited partner intends to subscribe for 0.245 billion yuan, with a subscription ratio not exceeding 49%; Chuchang private equity fund as a general partner and executive partner intends to subscribe for 5 million yuan.
jointown pharmaceutical group (600998) 2024 third quarter report review: Profitability improvement, reits and pre-reits projects are expected to bring additional volume.
Items: The company announced that the revenue, net profit attributable to mother, and net profit after deducting non-recurring gains and losses in the first three quarters of 2024 were 113.43, 1.7, 1.63 billion yuan, with year-on-year changes of -0.8%, -7.0%, -5.7%, among which the revenue and net profit in 3Q24.
Jointown Pharmaceutical Group (600998): REITS project accelerating landing, bullish on continuous improvement in operation.
On October 26, the company released its third quarter financial report for 2024, achieving a revenue of 113.429 billion yuan in the first three quarters of 2024, a year-on-year decrease of 0.82%, and achieving a net income attributable to the parent company of 16.9 billion yuan.
jointown pharmaceutical group (600998.SH) has accumulated repurchased 1.11% of its shares, costing 0.268 billion yuan.
Jointown Pharmaceutical Group (600998.SH) announced that as of October 31, 2024, the company has cumulatively repurchased shares...
No Data
No Data